Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Protara Therapeutics Inc.

An update from Protara Therapeutics ( ($TARA) ) is now available. On December 4, 2025, Protara Therapeutics entered into an Underwriting Agreement ...

Protara Therapeutics Completes $75 Million Stock Offering

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report) ...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Protara Therapeutics (TARA)

Protara Therapeutics ( ($TARA) ) has issued an update. On November 19, 2025, Protara Therapeutics announced interim results from its Phase 2 STARBO...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARA	$5.70	-5.16%	700.49K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARA	$5.70	-5.2%	700.49K
3
4
5
6

TARA

TARA

Dividend Overview

Get Protara Therapeutics Inc. Data in Excel

Get Protara Therapeutics Inc. Data in Excel